Wrong, Cramer! Livongo Rival Omada Health’s Physera Buy Aims At $200B Opportunity
- Sunday, July 19, 2020, 7:14
- Market
- Add a comment
Jim Cramer said that digital diabetes care provider, Livongo Health, has no competition. He’s wrong: Omada Health is one of many rivals.
About the Author
admin123 has written 23544 stories on this site.
